Allogene Therapeutics ALLO Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

O'Reilly AutomotiveORLY

$16.61M-33.4%

Boston ScientificBSX

$81M-29.6%

ALH

Alliance Laundry Holdings Inc.ALH

$125K—

KemperKMPR

$800K0.0%

ServiceNowNOW

$153M0.0%

Monolithic Power SystemsMPWR

$5.83M+9.3%

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's proceeds from issuance of common stock relating to employee stock plans?: Allogene Therapeutics (ALLO) reported proceeds from issuance of common stock relating to employee stock plans of $450K in Q1 2026.
How has Allogene Therapeutics's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Allogene Therapeutics's proceeds from issuance of common stock relating to employee stock plans decreased by 29.5% year-over-year, from $638K to $450K.